This study aimed to systematically re-assess HER2 biomarkers including HER2 ISH and ERBB2 mRNA, and correlate them to outcomes in trastuzumab-treated early HER2-positive breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.